Allogeneic tumor cells expressing fusogenic membrane glycoproteins as a platform for clinical cancer immunotherapy

Clinical Cancer Research

Volumn 12, Issue 4, 2006, Pages 1333-1341

  Errington, Fiona ^a   Bateman, Andrew ^c   Kottke, Tim ^b   Thompson, Jill ^b   Harrington, Kevin ^d   Merrick, Alison ^a   Hatfield, Paul ^a   Selby, Peter ^a   Vile, Richard ^b   Melcher, Alan ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b MAYO CLINIC   (United States)

^c SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; FUSOGENIC MEMBRANE GLYCOPROTEIN; IMMUNOLOGICAL ADJUVANT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MEMBRANE PROTEIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELL FUSION; CONTROLLED STUDY; GENE THERAPY; IMMUNOGENICITY; IN VIVO STUDY; MELANOMA B16; MEMBRANE VESICLE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYNCYTIOSOME; SYNCYTIUM; TUMOR REGRESSION; VESICULAR STOMATITIS VIRUS;

ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; CYTOPLASMIC VESICLES; GENE EXPRESSION; H-2 ANTIGENS; IMMUNOTHERAPY, ADOPTIVE; MELANOMA, EXPERIMENTAL; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; REMISSION INDUCTION; TIME FACTORS; TRANSFECTION; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIRAL ENVELOPE PROTEINS;

EID: 33644755625     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1113     Document Type: Article

References (24)

1. Bateman A, Bullough F, Murphy S, et al. Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth. Cancer Res 2000;60:1492-7.
2. Higuchi H, Bronk SF, Bateman A, Harrington K, Vile RG, Gores GJ. Viral fusogenic membrane glycoprotein expression causes syncytia formation with bioenergetic cell death: implications for gene therapy. Cancer Res 2000;60:6396-402.
3. Bateman AR, Harrington KJ, Kottke T, et al. Viral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cells. Cancer Res 2002;62:6566-78.
4. Diaz RM, Bateman A, Emiliusen L, et al. A lentiviral vector expressing a fusogenic glycoprotein for cancer gene therapy. Gene Ther 2000;7:1656-63.
5. Fielding AK, Chapel-Fernandes S, Chadwick MP, Bullough FJ, Cosset FL, Russell SJ. A hyperfusogenic gibbon ape leukemia envelope glycoprotein: targeting of a cytotoxic gene by ligand display. Hum Gene Ther 2000;11:817-26.
6. Srivastava P. Roles of heat-shock proteins in innate and adaptive immunity. Nat Rev Immunol 2002;2: 185-94.
7. Linardakis E, Bateman A, Phan V, et al. Enhancing the efficacy of a weak allogeneic melanoma vaccine by viral fusogenic membrane glycoprotein-mediated tumor cell-tumorcellfusion. Cancer Res 2002;62:5495-504.
8. Burzyn D, Rassa JC, Kim D, Nepomnaschy I, Ross SR, Piazzon I. Toll-like receptor 4-dependent activation of dendritic cells by a retrovirus. J Virol 2004;78: 576-84.
9. Fuchs EJ, Matzinger P. Is cancer dangerous to the immune system? Semin Immunol 1996;8:271-80.
10. Ahmed A, Jevremovic D, Suzuki K, et al. Intratumoral expression of a fusogenic membrane glycoprotein enhances the efficacy of replicating adenovirus therapy. Gene Ther 2003;10:1663-71.
11. Fu X, Tao L, Jin A, Vile R, Brenner MK, Zhang X. Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect. Mol Ther 2003;7:748-54.
12. Ebert O, Shinozaki K, Kournioti C, Park MS, Garcia-Sastre A, Woo SL. Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer. Cancer Res 2004;64:3265-70.
13. Phan V, Errington F, Cheong SC, et al. A new genetic method to generate and isolate small, short-lived but highly potent dendritic cell-tumor cell hybrid vaccines. Nat Med 2003;9:1215-9.
14. Plautz GE, Yang Z, Wu B, Gao X, Huang L, Nabel GJ. Immunotherapy of malignancy by in vivo gene transfer into tumours. Proc Natl Acad Sci U S A 1993;90: 4645-9.
15. Nabel GJ, Gordon D, Bishop DK, et al. Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc Natl Acad Sci USA 1996;93:15388-93.
16. Levitsky HI, Lazenby A, Hayashi RJ, Pardoll DM. In vivo priming of two distinct antitumour effector populations: the role of MHC class 1 expression. J Exp Med 1994;179:1215-24.
17. Daniels GA, Sanchez-Perez L, Diaz RM, et al. A simple method to cure established tumors by inflammatory killing of normal cells. Nat Biotechnol 2004;22: 1125-32
18. Altman DG. Analysis of survival times. In: Altman DG, editor. Practical statistics for medical research. London: Chapman and Hall: 1991. p. 365-95.
19. Thomas MC, Greten TF, Pardoll DM, Jaffee EM. Enhanced tumour protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine. Hum Gene Ther 1998;9:835-43.
20. Chaput N, Taieb J, Schartz NE, Andre F, Angevin E, Zitvogel L. Exosome-based immunotherapy. Cancer Immunol Immunother 2004;53:234-9.
21. Ahonen CL, Doxsee CL, McGurran SM, et al. Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN. J Exp Med 2004;199:775-84.
22. Chaput N, Schartz NE, Andre F, et al. Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naïve Tc1 lymphocytes leading to tumor rejection. J Immunol 2004; 172:2137-46.
23. Melief CJ. Mini-review: Regulation of cytotoxic T lymphocyte responses by dendritic cells: peaceful coexistence of cross-priming and direct priming? Eur J Immunol 2003;33:2645-54.
24. Stauss HJ. Immunotherapy with CTLs restricted by nonself MHC. Immunol Today 1999;20:180-3.